<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">HEPARIN SODIUM <img border="0" src="../images/pr.gif"/></span><br/><span class="topboxtradename">Hepalean <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Heparin Sodium Lock Flush Solution, </span><span class="topboxtradename">Hep-Lock, </span><span class="topboxtradename">Lipo-Hepin, </span><span class="topboxtradename">Liquaemin Sodium<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">anticoagulant</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 units/mL, 100 units/mL, 1000 units/mL 2000 units/mL, 5000 units/mL, 10,000 units/mL, 20,000 units/mL, 40,000 units/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Exerts direct effect on the cascade of blood coagulation (clotting) by enhancing the inhibitory actions of antithrombin III
         (heparin cofactor) on several factors essential to normal blood clotting, thereby blocking the conversion of prothrombin to
         thrombin and fibrinogen to fibrin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits formation of new clots. High molecular weight mucopolysaccharide with rapid anticoagulant effect. Does not lyse already
         existing thrombi but may prevent their extension and propagation.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis and treatment of venous thrombosis and pulmonary embolism and to prevent thromboembolic complications arising
         from cardiac and vascular surgery, frostbite, and during acute stage of MI. Also used in treatment of disseminated intravascular
         coagulation (DIC), atrial fibrillation with embolization, and as anticoagulant in blood transfusions, extracorporeal circulation,
         and dialysis procedures.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Prophylaxis in hip and knee surgery. Heparin Sodium Lock Flush Solution is used to maintain potency of indwelling IV catheters
         in intermittent IV therapy or blood sampling. It is not intended for anticoagulant therapy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to heparin (white clot syndrome); active bleeding, bleeding tendencies (hemophilia, purpura, thrombocytopenia);
         jaundice; ascorbic acid deficiency; inaccessible ulcerative lesions; visceral carcinoma; open wounds, extensive denudation
         of skin, suppurative thrombophlebitis; advanced kidney, liver, or biliary disease; active tuberculosis; bacterial endocarditis;
         continuous tube drainage of stomach or small intestines; threatened abortion; suspected intracranial hemorrhage, severe hypertension;
         recent surgery of eye, brain, or spinal cord; spinal tap; shock.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Alcoholism; history of allergy (asthma, hives, hay fever, eczema); during menstruation; pregnancy (category C) especially
         the last trimester, and immediate postpartum period; patients with indwelling catheters; older adults; use of acid-citrate-dextrose
         (ACD)-converted blood (may contain heparin); patients in hazardous occupations; cerebral embolism.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Treatment of Thromboembolism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 5000-U bolus dose, then 20,00040,000 U infused over 24 h, dose adjusted to maintain desired APTT or 500010,000
               U IV piggyback q46h <span class="rdroute">SC</span> 10,00020,000 U followed by 800020,000 U q812h<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 50 U/kg bolus, then 20,000 U/m<sup>2</sup>/24 h or 50100 U/kg q4h or 1525 U/kg/h<br/><br/><span class="indicationtitle">Open Heart Surgery</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 150300 U/kg<br/><br/><span class="indicationtitle">Prophylaxis of Embolism</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> 5000 U q812h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<ul>
<li>
            				Note: Before administration, check coagulation test values; if results are not within therapeutic range, notify physician for dosage
            adjustment. Do not use solutions of heparin or heparin lock-flush that contain benzyl alcohol preservative in neonates.
            			
         </li>
</ul><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Use more concentrated heparin solutions for SC injection.</li>
<li>Make injections into the fatty layer of the abdomen or just above the iliac crest. Avoid injecting within 5 cm (2 in) of umbilicus
            or in a bruised area. Insert needle into tissue roll perpendicular to skin surface. Do not withdraw plunger to check entry
            into blood vessel. Systematically rotate injection sites and keep record.
         </li>
<li>Exercise caution to avoid IM injection.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  <span class="methodtype">Intermittent/</span><span class="methodtype">Continuous:</span>   May add to any amount of NS, D5W, or Ringer's for injection.  Invert IV solution container at least 6 times to ensure adequate mixing. 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give a single dose over 60 sec.  <span class="methodtype">Intermittent/</span><span class="methodtype">Continuous:</span> Use infusion pump and give over 424 h.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Amikacin,</b>
<b>codeine,</b>
<b>chlorpromazine,</b>
<b>cytarabine,</b>
<b>diazepam,</b>
<b>dobutamine,</b>
<b>doxorubicin,</b>
<b>droperidol,</b>
<b>erythromycin,</b>
<b>gentamicin,</b>
<b>haloperidol,</b>
<b>hyaluronidase,</b>
<b>hydrocortisone,</b>
<b>kanamycin,</b>
<b>levorphanol,</b>
<b>mepbreak eridine,</b>
<b>methadone,</b>
<b>methicillin,</b>
<b>methotrimeprazine,</b>
<b>morphine,</b>
<b>netilmicin,</b>
<b>nitroglycerin,</b>
<b>pentazocine,</b>
<b>polymyxin B,</b>
<b>promethazine,</b>
<b>streptomycin,</b>
<b>tetracycline,</b>
<b>tobramycin,</b>
<b>triflupromazine,</b>
<b>vancomycin.</b>
<span class="incompattype">Y-site:</span>
<b>Amikacin,</b>
<b>dacarbazine,</b>
<b>diazepam,</b>
<b>diphenhydramine,</b>
<b>doxycycline,</b>
<b>doxorubicin,</b>
<b>droperidol,</b>
<b>ergotamine,</b>
<b>erythromycin,</b>
<b>gentamicin,</b>
<b>haloperidol,</b>
<b>kanamycin,</b>
<b>methotrimeprazine,</b>
<b>netilmicin,</b>
<b>nitroglycerin,</b>
<b>phenytoin,</b>
<b>polymyxin B,</b>
<b>streptomycin,</b>
<b>tobramycin,</b>
<b>triflupromazine,</b>
<b>vancomycin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F). Protect from freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span>
<span class="speceff-life">Spontaneous bleeding</span>, <span class="speceff-common">transient thrombocytopenia,</span> hypofibrinogenemia, "white clot syndrome." <span class="typehead">Body as a Whole:</span> Fever, chills, urticaria, pruritus, skin rashes, itching and burning sensations of feet, numbness and tingling of hands and
      feet, elevated BP, headache, nasal congestion, lacrimation, conjunctivitis, chest pains, arthralgia, <span class="speceff-life">bronchospasm, anaphylactoid reactions</span>. <span class="typehead">Endocrine:</span> Osteoporosis, hypoaldosteronism, suppressed renal function, hyperkalemia; rebound hyperlipidemia (following termination of
      heparin therapy). <span class="typehead">GI:</span> increased AST, ALT. <span class="typehead">Urogenital:</span> Priapism (rare). <span class="typehead">Skin:</span> Injection site reactions: pain, itching, ecchymoses, tissue irritation and sloughing; cyanosis and pains in arms or legs (vasospasm),
      reversible transient alopecia (usually around temporal area). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Notify laboratory that patient is receiving heparin, when a test is to be performed. Possibility of false-positive rise in
         <span class="alt">BSP</span> test and in <span class="alt">serum thyroxine;</span> and increases in <span class="alt">resin T<sub>3</sub>
</span>
<b>uptake;</b> false-negative <span class="alt">
<sup>125</sup>I fibrinogen uptake.</span> Heparin prolongs <span class="alt">PT.</span> Valid readings may be obtained by drawing blood samples at least 46 h after an IV dose (but at any time during heparin
         infusion) and 1224 h after an SC heparin dose.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May prolong PT, which is used to monitor therapy with <span class="classification">oral anticoagulants</span>; <b>aspirin,</b>
<span class="classification">nsaid</span>s increase risk of bleeding; <b>nitroglycerin</b> IV may decrease anticoagulant activity; <b>protamine</b> antagonizes effects of heparin. <span class="typehead">Herbal:</span>
<b>Feverfew,</b>
<b>ginkgo,</b>
<b>ginger,</b>
<b>valerian</b> may potentiate bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 2060 min SC. <span class="typehead">Peak:</span> Within minutes. <span class="typehead">Duration:</span> 26 h IV; 812 h SC. <span class="typehead">Distribution:</span> Does not cross placenta; not distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver and by reticuloendothelial system. <span class="typehead">Elimination:</span> Excreted slowly in urine. <span class="typehead">Half-Life:</span> 90 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline blood coagulation tests, Hct, Hgb, RBC, and platelet counts prior to initiation of therapy and at regular
            intervals throughout therapy.
         </li>
<li>Monitor APTT levels closely.</li>
<li>
            							Note: In general, dosage is adjusted to keep APTT between 1.52.5 times normal control level.
            						
         </li>
<li>Draw blood for coagulation test 30 min before each scheduled SC or intermittent IV dose and approximately q4h for patients
            receiving continuous IV heparin during dosage adjustment period. After dosage is established, tests may be done once daily.
         </li>
<li>Patients vary widely in their reaction to heparin; risk of hemorrhage appears greatest in women, all patients &gt;60 y, and patients
            with liver disease or renal insufficiency.
         </li>
<li>Monitor vital signs. Report fever, drop in BP, rapid pulse, and other S&amp;S of hemorrhage.</li>
<li>Observe all needle sites daily for hematoma and signs of inflammation (swelling, heat, redness, pain).</li>
<li>Antidote: Have on hand protamine sulfate (1% solution), specific heparin antagonist.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Protect from injury and notify physician of pink, red, dark brown, or cloudy urine; red or dark brown vomitus; red or black
            stools; bleeding gums or oral mucosa; ecchymoses, hematoma, epistaxis, bloody sputum; chest pain; abdominal or lumbar pain
            or swelling; unusual increase in menstrual flow; pelvic pain; severe or continuous headache, faintness, or dizziness.
         </li>
<li>
            							Note: Menstruation may be somewhat increased and prolonged; usually, this is not a contraindication to continued therapy if bleeding
            is not excessive.
            						
         </li>
<li>Learn correct technique for SC administration if discharged from hospital on heparin.</li>
<li>Engage in normal activities such as shaving with a safety razor in the absence of a low platelet (thrombocyte) count. Usually,
            heparin does not affect bleeding time.
         </li>
<li>Caution: Smoking and alcohol consumption may alter response to heparin and are not advised.</li>
<li>Do not take aspirin or any other OTC medication without physician's approval.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>